EUVIMEDAtrasti EUVIMED
Open access

Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States

Samer Gawrieh iD, Eduardo Vilar-Gomez iD, Tinsay A Woreta, Jordan E Lake, Laura A Wilson, Jennifer C Price iD, Susanna Naggie, Richard K Sterling, Sonya Heath, Kathleen E Corey, Edward R Cachay, Veeral Ajmera and 4 more

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17849 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Samer Gawrieh and 15 co-authors. Institution: Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, HIV Infections, Metabolic Diseases. Cited 68 times so far (Crossref); 48 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, NIAAA NIH HHS, NHLBI NIH HHS.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

Metabolic dysfunction‐associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD.

Aims

To assess the effects of this new nomenclature on the prevalence and distribution of different SLD categories in people with HIV (PWH) and identified factors associated with MASLD and clinically significant fibrosis (CSF).

Methods

PWH were prospectively enrolled from 9 US centres and underwent clinical evaluation and vibration‐controlled transient elastography for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). SLD was defined as CAP ≥ 263 dB/m, CSF as LSM of ≥8 kPa, and advanced fibrosis (AF) as LSM ≥ 12 kPa. The prevalence of SLD, MASLD, metabolic dysfunction and alcohol‐associated liver disease (MetALD), ALD, cryptogenic (cSLD), CSF and AF were determined. Uni‐ and multivariate logistic regression models were used to assess factors associated with MASLD and CSF risk.

Results

Of 1065 participants, 74% were male, mean (SD) age 51.6 ± 11.9 years, 46% non‐Hispanic Black and 74% with undetectable HIV RNA. The prevalence of SLD was 52%, MASLD 39%, MetALD 10%, ALD 3%, CSF 15% and AF 4%. Only 0.6% had cSLD. Black race was protective whereas obesity, ALT and AST levels were associated with increased risk of MASLD and CSF in MASLD. HIV or antiretroviral therapy did not affect MASLD risk.

Conclusions

MASLD and MetALD are the dominant causes of SLD in PWH, affecting almost half. Application of the new nomenclature resulted in minimal change in the proportion of patients with MASLD who would have been diagnosed previously with NAFLD.

Subjects

MeSH terms (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHIV InfectionsMetabolic DiseasesHumansMaleUnited StatesAdultMiddle AgedFemaleLiver CirrhosisPrevalenceObesityLiver

Author keywords

CAPMASLDNAFLDcirrhosisfibrosismetALDprevalencestiffness

Authors and institutions

  • Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Division of Division of Gastroenterology and Hepatology, John Hopkins University, Baltimore, Maryland, USA.
  • Division of Infectious Diseases, Department of Medicine, UTHealth, Houston, Texas, USA.
  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA.
  • Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID profiles: Samer Gawrieh, Eduardo Vilar-Gomez, Jennifer C Price, Mark S Sulkowski, Naga Chalasani, Rohit Loomba

Funding

  • NIDDK NIH HHS
  • NIAAA NIH HHS
  • NHLBI NIH HHS
  • NIDA NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Gawrieh, S., Vilar-Gomez, E., Woreta, T. A., Lake, J. E., Wilson, L. A., Price, J. C., Naggie, S., Sterling, R. K., Heath, S., Corey, K. E., Cachay, E. R., Ajmera, V., Tonascia, J., Sulkowski, M. S., Chalasani, N., & Loomba, R. (2024). Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17849

Vancouver

Gawrieh S, Vilar-Gomez E, Woreta TA, Lake JE, Wilson LA, Price JC, et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17849

BibTeX
@article{Gawrieh2024,
  author = {Gawrieh, Samer and Vilar-Gomez, Eduardo and Woreta, Tinsay A and Lake, Jordan E and Wilson, Laura A and Price, Jennifer C and Naggie, Susanna and Sterling, Richard K and Heath, Sonya and Corey, Kathleen E and Cachay, Edward R and Ajmera, Veeral and Tonascia, James and Sulkowski, Mark S and Chalasani, Naga and Loomba, Rohit},
  title = {Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17849}
}
Start for free →